Covered recipient · General Payments record
ANTONIO UCAR
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$338.65
12 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $245.66 | 11 |
| Education | $92.99 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SEAGEN INC. | $92.99 | 1 |
| E.R. Squibb & Sons, L.L.C. | $73.32 | 3 |
| Eisai Inc. | $41.14 | 2 |
| ARRAY BIOPHARMA INC | $34.02 | 2 |
| Daiichi Sankyo Inc. | $28.81 | 1 |
| JAZZ PHARMACEUTICALS INC. | $28.76 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.66 | 1 |
| Astellas Pharma US Inc | $17.95 | 1 |
Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANTONIO UCAR
NPI 1851388052 · CMS profile ID 174494
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1851388052?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANTONIO UCAR, NPI 1851388052, CMS profile ID 174494. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851388052?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ANTONIO UCAR, NPI 1851388052, CMS profile ID 174494. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851388052?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ANTONIO UCAR, NPI 1851388052, CMS profile ID 174494, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1851388052?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
12 matching records · $338.65 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–12 of 12.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.11 | 11/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184921280 | CMS |
| SEAGEN INC. | $92.99 | 10/01/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230638010 | CMS |
| ARRAY BIOPHARMA INC | $14.24 | 07/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230589410 | CMS |
| Eisai Inc. | $20.61 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244462238 | CMS |
| ARRAY BIOPHARMA INC | $19.78 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230582205 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.66 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223871637 | CMS |
| JAZZ PHARMACEUTICALS INC. | $28.76 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234324009 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.79 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184921220 | CMS |
| Astellas Pharma US Inc | $17.95 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238781091 | CMS |
| Daiichi Sankyo Inc. | $28.81 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197061453 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.42 | 02/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184921188 | CMS |
| Eisai Inc. | $20.53 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244462235 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $9,965.00 | 3 |
| PY2024 | Principal investigator | $1,550.11 | 1 |
| PY2023 | Principal investigator | $39,322.66 | 15 |
| PY2022 | Principal investigator | $115,764.68 | 28 |
| PY2021 | Principal investigator | $335,321.36 | 25 |
| PY2020 | Principal investigator | $136,618.26 | 10 |
| PY2019 | Principal investigator | $491,637.80 | 28 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
28 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $682.14 | 12/19/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949763873 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $212.00 | 12/06/2022 | Non-covered Recipient Entity BAPTIST HEALTH MEDICAL GROUP ONCOLOGY LLC | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | No dispute reported | 06/30/2026 | 953501607 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $212.00 | 12/06/2022 | Non-covered Recipient Entity BAPTIST HEALTH MEDICAL GROUP ONCOLOGY LLC | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | No dispute reported | 06/30/2026 | 953501613 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $436.00 | 12/06/2022 | Non-covered Recipient Entity BAPTIST HEALTH MEDICAL GROUP ONCOLOGY LLC | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | No dispute reported | 06/30/2026 | 953501617 |
| Principal investigator 1 | Ipsen Bioscience Inc | $1,125.00 | 11/21/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 881885993 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $129.00 | 11/07/2022 | Non-covered Recipient Entity Us Oncology | Phase II/III 1L MSS CRC Nivo+ SOC vs SOC - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 933191757 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,189.00 | 09/27/2022 | Non-covered Recipient Entity Baptist Hospital Of Miami | Phase III MSS 3L CRC Rela+Nivo vs. regorafenib/TAS-102 - A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Nivolumab Fixed Dosed Combination versus Regorafenib or Trifluridine plus Tipiracil for Participants with Later-Lines of Metastatic Color | No dispute reported | 06/30/2026 | 933194965 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,913.00 | 08/25/2022 | Non-covered Recipient Entity Wcg Irb | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) | No dispute reported | 06/30/2026 | 933187391 |
| Principal investigator 1 | Ipsen Bioscience Inc | $8,795.00 | 08/10/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 881885795 |
| Principal investigator 1 | Ipsen Bioscience Inc | $1,125.00 | 08/10/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 881885797 |
| Principal investigator 1 | PFIZER INC. | $619.65 | 07/18/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949763859 |
| Principal investigator 1 | PFIZER INC. | $619.65 | 07/18/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949763861 |
| Principal investigator 1 | BeiGene, Ltd. | $7,261.51 | 06/20/2022 | Non-covered Recipient Entity MIAMI CANCER INSTITUTE AT BAPTIST HEALTH INC | PARALLEL 303: A Phase 2, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy | No dispute reported | 06/30/2026 | 933750685 |
| Principal investigator 1 | PFIZER INC. | $11,357.50 | 05/11/2022 | Non-covered Recipient Entity Miami Cancer Institute at Baptist Health Inc | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949750427 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,750.00 | 04/15/2022 | Non-covered Recipient Entity MIAMI CANCER INSTITUTE, BAPTIST HEALTH SOUTH FLORIDA | Phase II III 1L MSS CRC Nivo SOC vs SOC - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 933191217 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,217.00 | 04/15/2022 | Non-covered Recipient Entity MIAMI CANCER INSTITUTE, BAPTIST HEALTH SOUTH FLORIDA | Phase III 1L Gastric nivo ipi vs nivo CT vs CT | No dispute reported | 06/30/2026 | 933193075 |
| Principal investigator 1 | PFIZER INC. | $14,721.60 | 03/28/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949815953 |
| Principal investigator 1 | PFIZER INC. | $489.12 | 03/28/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949816249 |
| Principal investigator 1 | PFIZER INC. | $124.16 | 03/28/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949816299 |
| Principal investigator 1 | PFIZER INC. | $619.65 | 03/08/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949815937 |
| Principal investigator 1 | PFIZER INC. | $40,121.16 | 03/08/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949815955 |
| Principal investigator 1 | PFIZER INC. | $227.40 | 03/08/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949816063 |
| Principal investigator 1 | PFIZER INC. | $576.00 | 03/08/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949816251 |
| Principal investigator 1 | PFIZER INC. | $682.14 | 03/08/2022 | Non-covered Recipient Entity Miami Cancer Institute | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 949816301 |
| Principal investigator 1 | Ipsen Bioscience Inc | $1,125.00 | 02/11/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 881885943 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,957.00 | 01/18/2022 | Non-covered Recipient Entity Us Oncology Res Llc | Phase II III 1L MSS CRC Nivo SOC vs SOC - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 933191241 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,452.00 | 01/18/2022 | Non-covered Recipient Entity Us Oncology Res Llc | Phase III 1L Gastric nivo ipi vs nivo CT vs CT | No dispute reported | 06/30/2026 | 933193167 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $2,026.00 | 01/12/2022 | Non-covered Recipient Entity BAPTIST HEALTH MEDICAL GROUP ONCOLOGY LLC | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | No dispute reported | 06/30/2026 | 953480799 |